Trevi Therapeutics, Inc. (TRVI) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.83B USD. 52-week range 9.28 to 20.22 USD. Data as of 2026-10-09.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and ...